Ukkunagar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 20-05-2024
- Paid Up Capital ₹ 1.40 M
as on 20-05-2024
- Company Age 22 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 11.37%
(FY 2017)
- Profit 113.90%
(FY 2017)
- Ebitda 19.09%
(FY 2017)
- Net Worth 15.81%
(FY 2017)
- Total Assets 2.18%
(FY 2017)
About Ukkunagar Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.40 M, as per Ministry of Corporate Affairs (MCA) records.
Satyanarayana Chaparala, Surya Kakarlapudi, Satya Valati, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24239AP2002PTC038764
- Company No.
038764
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ukkunagar Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Thirupathi Bommi  | Managing Director | 29-Mar-2012 | Current |
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satyanarayana Chaparala | Director | 09-Apr-2002 | Current |
| Surya Kakarlapudi | Director | 12-Aug-2016 | Current |
| Satya Valati | Director | 29-Mar-2012 | Current |
| Suri Boddu | Director | 28-Sep-2007 | Current |
| Rama Vemulapalli | Director | 12-Jun-2005 | Current |
| Veeru Manthini | Director | 09-Apr-2002 | Current |
Financial Performance of Ukkunagar Pharmaceuticals.
Ukkunagar Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 11.37% increase. The company also saw a substantial improvement in profitability, with a 113.9% increase in profit. The company's net worth Soared by an impressive increase of 15.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ukkunagar Pharmaceuticals?
In 2017, Ukkunagar Pharmaceuticals had a promoter holding of 10.75% and a public holding of 89.25%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Steel City Pharmaceuticals Pvt LtdActive 30 years 11 monthsSatyanarayana Chaparala, Surya Kakarlapudi and 3 more are mutual person
- Ukkunagar Chits Private LimitedActive 26 years 6 months
Suri Boddu, Thirupathi Bommi and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ukkunagar Pharmaceuticals?
Unlock and access historical data on people associated with Ukkunagar Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ukkunagar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ukkunagar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
